New shot targets tough prostate cancer
NCT ID NCT06029998
Summary
This study is testing if a drug called bortezomib, given as an injection, can help control advanced prostate cancer that has stopped responding to standard hormone treatments and has a specific genetic change called PTEN deletion. Researchers want to see if the treatment causes a meaningful drop in a blood marker called PSA. The trial will involve about 22 men who will receive injections for up to 8 cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute/University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.